ST-246 Polymorph Crystallization for Stable Tablet Processing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing technologies do not account for the existence of multiple polymorphic forms of ST-246, which can affect physical properties such as flow characteristics, compression characteristics, stability, and solubility, and there is a need for crystallization and characterization of new polymorphic forms of ST-246 to improve pharmaceutical formulations.

Innovation Solution

The development of polymorphic forms of ST-246, which includes the crystalline forms of ST-246, which includes the crystalline forms of ST-246, which includes the crystalline forms of ST-246, which are characterized by their X-ray powder diffraction patterns, which are characterized by their crystalline forms of ST-246, which are characterized by their X-ray powder diffraction patterns, and their use in pharmaceutical compositions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If multiple polymorphic forms of ST-246 are discovered and characterized, then the physico-chemical properties and pharmaceutical processing can be improved, but the complexity of the system increases due to the need to manage and control different crystalline forms

Engineering Contradiction:

Improvepharmaceutical formulation stabilityVSAvoidpolymorph control complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by controlling crystallization conditions (temperature, solvent composition, pH, presence of additives) to selectively obtain specific polymorphic forms of ST-246. By adjusting these parameters, the patent achieves desired physical properties such as improved flow characteristics, compression characteristics, and stability for pharmaceutical formulations.

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If crystallization processes are optimized to obtain specific polymorphic forms, then manufacturing precision of crystalline structures is improved, but the process complexity and time required increase

Engineering Contradiction:

Improvecrystalline form controlVSAvoidcrystallization process time

Core Design Contradiction:

Manufacturing precisionVSLoss of time

Solution Approach 1:

The patent employs preliminary action by pre-preparing controlled crystallization conditions, including selecting appropriate solvents, adjusting pH levels, and preparing seed crystals before the actual crystallization process. This allows for targeted formation of specific polymorphic forms (Form I, II, III, IV, V, or VI) with desired properties while reducing overall process time through optimized protocols.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The new polymorphic forms of ST-246 provide improved physico-chemical and pharmaceutical processing, enhancing mechanical handling, compression characteristics, and stability, and allowing for targeted release profiles in pharmaceutical dosage forms.

Implementation Method 1

crystalline forms of ST-246, which are characterized by their X-ray powder diffraction patterns

Methodology Applied

Scientific EffectX-ray diffraction: X-Ray

Data Source

PatentUS20260000644A1Polymorphic forms of st-246 and methods of preparation

Publication Date: 2026.01.01 SIGA TECHNOLOGIES INC

AI summary

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2 (1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.